Phase <scp>II</scp> study (<scp>KAMELEON</scp>) of single‐agent <scp>T‐DM1</scp> in patients with <scp>HER2</scp>‐positive advanced urothelial bladder cancer or pancreatic cancer/cholangiocarcinoma
Cancer medicine